Early molecular diagnosis and biological sub-typing of the tumor is a crucial component in the overall prospects for life extending therapy. We encourage parents to contact us as soon as their child is diagnosed. Upon presenting to us, children will typically undergo a biopsy to determine the sub type of DIPG and the best available treatment regimen specific to their sub-type. The DCEz and DRIz are working intensively to gain greater diagnostic patient visibility at all stages after the initial biopsy to ascertain the efficacy of each treatment stage promptly and monitor changes in the disease mutation.
We believe that the historical reliance on MRI and clinical condition assessment need further integration into emerging technologies to make therapeutic progress at the speed that we have committed to. Much better diagnostic visibility is a mandatory development in pursuing the pathway to greater life extension.